Absci opens door to new biotechnology campus

Headquartered in Vancouver, Washington, will expand the company’s ability to accelerate the discovery and development of next generation biological medicines

VANCOUVER, Wash., Oct. 20, 2021 (GLOBE NEWSWIRE) – Absci Corporation (Nasdaq: ABSI), the drug and target discovery company that leverages deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced today the opening of. announced its new campus in Vancouver, Washington, a few miles east of downtown, which has housed the company for the past four years.

“Absci has been an incredibly positive force in the Vancouver community since he set up his headquarters here in 2016,” said Washington Governor Jay Inslee. “I have followed Absci’s progress as it expanded inward and has now outgrown this original Vancouver facility. Not only does Absci attract investment and top talent to Washington, but it also continuously innovates and creates exciting new opportunities for the future of medicine. I look forward to cutting the ribbon on the new Absci campus early next month and continuing to support the development of our biotechnology ecosystem here in Washington. “

The new Absci facility was designed and built in close collaboration between the company, the Portland design firm Bora Architecture & Interiors and the local contractor Bremik Construction. It comprises over 85,000 square meters of laboratory, office and meeting space and offers regional, renewable and natural building materials, bespoke surfaces and a lively aesthetic.

The scalable laboratory space is designed to maximize flow, increase capacity and easily reconfigure if necessary. In addition to tripling the capacity for program execution, integrating internal tissue culture capacities, high-throughput analytical instruments, advanced liquid handling and automation, and a dedicated clean air fermentation facility in conjunction with a state-of-the-art offsite computing cluster, the expanded scope of Absci’s research and development activities facilitate . In addition, integrated technologies for capturing large amounts of data throughout Absci’s workflow generate input for ongoing training of Absci’s Denovium EngineTM deep learning AI models for drug discovery and cell line design.

“It’s inspiring to come to work every day in this extraordinary building,” said Sean McClain, Founder and CEO of Absci. “We designed the light-flooded room around collaboration and the pursuit of scientific excellence, and we are enthusiastic about the pride that our Unlimiters have on this new campus. We strive every day to learn new things about challenging problems, and this collaboration really encourages us all to go beyond the impossible to create new opportunities for patients. “

“When I visited the Absci campus, I was impressed with the quality and productivity that makes up the space,” commented Bharat Dixit of ClearB Therapeutics. “The interior is designed in a modern way, but with practical aspects in mind – the futuristic changing rooms, the bright, open laboratory rooms with lots of natural light and intuitive flow, as well as the latest robotic equipment, to name a few. And the friendly town hall full of people exchanging ideas seems to be a sign of great success. “

About absci

Absci is the drug and target discovery company using deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We developed our Integrated Drug Creation ™ platform to identify novel drug targets, discover optimal biotherapeutic candidates and generate the cell lines for their production in a single efficient process. Biotech and pharmaceutical innovators are working with us to develop the next generation of protein-based drugs, including Bionic Proteins ™, which contain non-standard amino acids and other novel drug designs that other technologies may not be able to produce. Our goal is to enable the development of better drugs through Translating Ideas into Drugs ™. More information is available at www.absci.com.

Availability of more information on Absci

Investors and others should note that we routinely communicate with investors and the public through our website (www.absci.com) and our investor relations website (investors.absci.com), in particular through the publication of investor presentations, SEC filings , Press releases, public conference calls and webcasts on these websites. The information that we publish on these websites can be considered material information. Therefore, investors, the media and others interested in Absci are encouraged to review this information regularly. The content of our website or any other website accessible from our website is not deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended.

Forward-looking statements by Absci

Certain statements in this press release that are not historical facts are deemed forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that contain the The words “will”, “may”, “pursue”, “anticipate”, “plan”, “believe”, “predict”, “estimate”, “expect” and “intend” or similar expressions. We intend that these forward-looking statements, including statements about drug development efforts, be covered by the safe harbor provisions for forward-looking statements in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we are making this statement. for the purpose of complying with these Safe Harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects based on the information currently available to us and on assumptions we have made. We cannot guarantee that the plans, intentions, expectations or strategies will be achieved or achieved, and furthermore, actual results could differ materially from those described in the forward-looking statements and are influenced by a variety of risks and factors outside of ours Control, including but not limited to risks and uncertainties related to drug development efforts; along with the risks outlined in our quarterly report on Form 10-Q of the 7th Securities and Exchange Commission. Unless required by law, we assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or for any other reason.

Investor contact

[email protected]

Media contact

[email protected]

Comments are closed.